Cardiovascular pharmacogenetics of antihypertensive and lipid- lowering therapies
Title | Cardiovascular pharmacogenetics of antihypertensive and lipid- lowering therapies |
Publication Type | Journal Article |
Year of Publication | 2014 |
Authors | Vanichakarn P, Hwa J, Stitham J |
Journal | Curr Mol Med |
Volume | 14 |
Issue | 7 |
Pagination | 849-79 |
Date Published | 2014 |
ISSN | 1875-5666 |
Abstract | Recent changes to the clinical management guidelines for hypertension and hyperlipidemia have placed emphasis on prevention through the pharmacological control and reduction of cardiovascular risk factors. In conjunction with proper diet and lifestyle changes, such risk factor control necessitates the use of safe and effective pharmacotherapy. However, many patients fail to reach or maintain therapeutic goals due to inadequacy and/or variability in response to antihypertensive and lipid-lowering medications. Thus, given the contribution of both hypertension and hyperlipidemia in the development and progression of cardiovascular disease, a personalized approach to pharmacotherapy, as well as disease prevention, seems particularly prudent. With the advancement of cardiovascular pharmacogenetics, the aim is to identify genetic biomarkers of drug-response and disease-susceptibility in order to make informed and individualized decisions, improving patient care through proper drug selection and dosing. |
Alternate Journal | Curr. Mol. Med. |
PubMed ID | 25109793 |
Grant List | R01 HL074190 / HL / NHLBI NIH HHS / United States R01 HL115247 / HL / NHLBI NIH HHS / United States R01HL074190 / HL / NHLBI NIH HHS / United States R01HL115247 / HL / NHLBI NIH HHS / United States T32HL00795011 / HL / NHLBI NIH HHS / United States U54 HL117798 / HL / NHLBI NIH HHS / United States U54HL117798 / HL / NHLBI NIH HHS / United States |